尿液中的整合素αV：一种用于前列腺癌检测的新型无创标志物。
Integrin Alpha V in Urine: A Novel Noninvasive Marker for Prostate Cancer Detection.
作者信息
Zemskova Marina Y, Marinets Maria V, Sivkov Andrey V, Pavlova Julia V, Shibaev Andrey N, Sorokin Konstantin S
机构信息
G.K. Skryabin Institute of Biochemistry and Physiology of Microorganisms, Federal Research Center, Pushchino Center for Biological Research of the Russian Academy of Sciences, Pushchino, Russia.
Department of the Research, Prostagnost LLC, Moscow, Russia.
出版信息
Front Oncol. 2021 Mar 10;10:610647. doi: 10.3389/fonc.2020.610647. eCollection 2020.
UNLABELLED
Prostate cancer (PCa) diagnosis based on patient urine analysis provides non-invasive and promising method as compared to biopsy and a prostate-specific antigen (PSA) test. This study was conceived to investigate whether Integrin alpha V (ITGAV) protein is present in urine and assess the urinary ITGAV diagnostic potential for PCa.
MATERIALS AND METHODS
Urinary ITGAV expression was determined by Western blot analysis and quantified by ELISA in urine from men with PCa (n = 47), benign prostate hyperplasia (n = 42) and age-matched controls (n = 22).
RESULTS
The level of ITGAV protein was significantly lower in PCa urine samples as compared to those in the control group (p < 0.00001). The decrease of ITGAV in urine was highly predictive of PCa with 91.5% sensitivity, 91.4% specificity, 0.93 area under the ROC curve, and its specificity was better than that of serum PSA.
CONCLUSION
Urinary ITGAV provides a novel noninvasive biomarker with high specificity.
未标记
与活检和前列腺特异性抗原（PSA）检测相比，基于患者尿液分析的前列腺癌（PCa）诊断提供了一种非侵入性且有前景的方法。本研究旨在调查整合素αV（ITGAV）蛋白是否存在于尿液中，并评估尿液ITGAV对PCa的诊断潜力。
材料与方法
采用蛋白质印迹分析确定尿液中ITGAV的表达，并通过酶联免疫吸附测定（ELISA）对前列腺癌患者（n = 47）、良性前列腺增生患者（n = 42）和年龄匹配的对照组（n = 22）的尿液进行定量分析。
结果
与对照组相比，PCa尿液样本中ITGAV蛋白水平显著降低（p < 0.00001）。尿液中ITGAV的降低对PCa具有高度预测性，敏感性为91.5%，特异性为91.4%，ROC曲线下面积为0.93，其特异性优于血清PSA。
结论
尿液ITGAV提供了一种具有高特异性的新型非侵入性生物标志物。
Zotero 插件